OSF HealthCare Joins Nationwide Trial for Heart Failure Patients
OSF HealthCare today announced its first successful implantation of a new device designed for proactive heart failure management, as part of a nationwide research study. The implant occurred at OSF HealthCare Saint Francis Medical Center in Peoria on Monday, March 15.
The study, called PROACTIVE HF, focuses on the new Cordella® Pulmonary Artery Pressure Sensor System (Cordella Sensor), which is a wireless sensor implanted during a minimally invasive right heart catheterization procedure. The Cordella Sensor measures pulmonary artery (PA) pressure, and is part of the comprehensive Cordella® Heart Failure System (Cordella System).
The Cordella System enables better clinician-patient communication with user-friendly tools that provide a comprehensive patient health status, including blood pressure, weight, heart rate and symptoms, to remotely optimize medication and provide early insight into worsening symptoms.
OSF Saint Francis is one of 70 sites across the country participating in the trial to study the safety and efficacy of the Cordella Sensor in more than 950 patients.
“The health status of heart failure patients can change quickly, and we need better insight into the patient’s daily health condition to improve care, and provide interventions before worsening heart failure occurs. PA pressure data can provide an early indication of that,” remarked Christopher Sparrow, M.D., an OSF HealthCare Cardiovascular Institute heart failure specialist and implanting physician for the trial. “We are excited to be part of this trial to improve the standard of care for chronic heart failure patients. The Cordella Sensor and System is designed to better manage patients, so we can remotely adjust therapy and keep them out of the hospital.”
In addition, the wireless, implantable Cordella Sensor allows patients to share daily PA pressure measurements using a handheld reader. When used together this information informs the clinician, encourages proactive heart failure management between office visits and aims to improve patient outcomes.
The Cordella Sensor is part of a PROACTIVE-HF Pivotal Trial sponsored by Endotronix, a company dedicated to heart failure management and solutions.
The trial is assessing the benefits of PA pressure-guided management with the Cordella Sensor for New York Heart Association (NYHA) Class III heart failure patients. In addition, the study will evaluate secondary endpoints such as the rate of HF-related hospitalizations, device performance, and patient quality of life.